Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Kvaløy S[au]:

Search results

Items: 1 to 50 of 129

1.

The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy.

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A.

Br J Haematol. 2018 Oct;183(2):225-234. doi: 10.1111/bjh.15518. Epub 2018 Aug 6.

PMID:
30080252
2.

Factors influencing access to palliative radiotherapy: a Norwegian population-based study.

Åsli LM, Myklebust TÅ, Kvaløy SO, Jetne V, Møller B, Levernes SG, Johannesen TB.

Acta Oncol. 2018 Sep;57(9):1250-1258. doi: 10.1080/0284186X.2018.1468087. Epub 2018 Apr 28.

PMID:
29706109
3.

Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB.

Acta Oncol. 2018 Jun;57(6):773-781. doi: 10.1080/0284186X.2017.1406137. Epub 2017 Nov 24.

PMID:
29171324
4.

Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation.

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, Kiserud CE, Lund MB.

Bone Marrow Transplant. 2017 Apr;52(4):646-649. doi: 10.1038/bmt.2016.338. Epub 2016 Dec 19. No abstract available.

PMID:
27991891
5.

Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial.

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S.

Clin Microbiol Infect. 2017 Mar;23(3):179-187. doi: 10.1016/j.cmi.2016.10.019. Epub 2016 Oct 26.

6.

Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation.

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE.

Br J Cancer. 2016 Jul 12;115(2):178-87. doi: 10.1038/bjc.2016.180. Epub 2016 Jun 28.

7.

Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation.

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA.

Acta Oncol. 2016 May;55(5):547-53. doi: 10.3109/0284186X.2015.1125015.

PMID:
27123741
8.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H.

Br J Haematol. 2016 May;173(3):432-43. doi: 10.1111/bjh.13965. Epub 2016 Feb 23.

PMID:
26914167
9.

Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study.

Murbraech K, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falk RS, Aakhus S, Kiserud CE.

J Clin Oncol. 2015 Aug 20;33(24):2683-91. doi: 10.1200/JCO.2015.60.8125. Epub 2015 Jul 13.

PMID:
26169610
10.

Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway.

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H.

Haematologica. 2015 Jun;100(6):e240-3. doi: 10.3324/haematol.2014.119214. Epub 2015 Feb 14. No abstract available.

11.

Utilization of radiation therapy in Norway after the implementation of the national cancer plan--a national, population-based study.

Asli LM, Kvaløy SO, Jetne V, Myklebust TÅ, Levernes SG, Tveit KM, Green TO, Johannesen TB.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):707-14. doi: 10.1016/j.ijrobp.2014.06.059. Epub 2014 Aug 23.

PMID:
25160610
12.

Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma.

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF.

Acta Oncol. 2014 May;53(5):680-7. doi: 10.3109/0284186X.2013.855816. Epub 2013 Nov 18.

PMID:
24237392
13.

Atherosclerotic lesions in lymphoma survivors treated with radiotherapy.

Wethal T, Nedregaard B, Andersen R, Fosså A, Lund MB, Günther A, Kvaløy S, Fosså SD, Kjekshus J.

Radiother Oncol. 2014 Mar;110(3):448-54. doi: 10.1016/j.radonc.2013.10.029. Epub 2013 Nov 11.

PMID:
24231235
14.

High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment.

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1735-9. doi: 10.4045/tidsskr.13.0319. English, Norwegian.

15.

High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008.

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H.

Tidsskr Nor Laegeforen. 2013 Sep 3;133(16):1704-9. doi: 10.4045/tidsskr.13.0243. English, Norwegian.

16.

The Norwegian experience with penicillin G plus an aminoglycoside as initial empiric therapy in febrile neutropenia; a review.

Torfoss D, Høiby EA, Holte H, Kvaløy S.

Acta Oncol. 2012 Apr;51(4):433-40. doi: 10.3109/0284186X.2011.633931. Epub 2011 Dec 19. Review.

PMID:
22175253
17.

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N; MabThera International Trial (MInT) Group.

Lancet Oncol. 2011 Oct;12(11):1013-22. doi: 10.1016/S1470-2045(11)70235-2. Epub 2011 Sep 21.

PMID:
21940214
18.

The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily.

Torfoss D, Sandstad B, Mollnes TE, Høiby EA, Holte H, Bjerner J, Bjøro T, Gaudernack G, Kvalheim G, Kvaløy S.

Scand J Immunol. 2011 Dec;74(6):632-9. doi: 10.1111/j.1365-3083.2011.02618.x.

19.

Effects of a computer-supported interactive tailored patient assessment tool on patient care, symptom distress, and patients' need for symptom management support: a randomized clinical trial.

Ruland CM, Holte HH, Røislien J, Heaven C, Hamilton GA, Kristiansen J, Sandbaek H, Kvaløy SO, Hasund L, Ellison MC.

J Am Med Inform Assoc. 2010 Jul-Aug;17(4):403-10. doi: 10.1136/jamia.2010.005660.

20.

Priming with r-metHuSCF and filgrastim or chemotherapy and filgrastim in patients with malignant lymphomas: a randomized phase II pilot study of mobilization and engraftment.

Johnsen HE, Geisler C, Juvonen E, Remes K, Juliusson G, Hörnsten P, Kvaloy S, Kvalheim G, Jürgensen GW, Pedersen LM, Bergmann OJ, Schmitz A, Boegsted M.

Bone Marrow Transplant. 2011 Jan;46(1):44-51. doi: 10.1038/bmt.2010.84. Epub 2010 May 3.

PMID:
20436517
21.

Pain after palliative radiotherapy for spine metastases.

Zaikova O, Fosså SD, Kongsgaard U, Kvaløy S, Giercksky KE, Skjeldal S.

Clin Oncol (R Coll Radiol). 2010 Dec;22(10):828-36. doi: 10.1016/j.clon.2010.03.008. Epub 2010 Apr 3.

PMID:
20363110
22.

[Use of radiotherapy in South-Eastern Norway Regional Health Authority].

Jetne V, Kvaløy S, Smeland S, Johannesen TB, Tveit KM.

Tidsskr Nor Laegeforen. 2009 Dec 17;129(24):2602-5. doi: 10.4045/tidsskr.09.0331. Norwegian.

23.

[Molecular diagnosis of malignant lymphomas].

Holte H, Kvaløy S, Delabie J, Trøen G, Smeland EB.

Tidsskr Nor Laegeforen. 2009 Nov 19;129(22):2352-6. doi: 10.4045/tidsskr.09.0704. Review. Norwegian.

24.

A population-based study of spinal metastatic disease in South-East Norway.

Zaikova O, Giercksky KE, Fosså SD, Kvaløy S, Johannesen TB, Skjeldal S.

Clin Oncol (R Coll Radiol). 2009 Dec;21(10):753-9. doi: 10.1016/j.clon.2009.09.023. Epub 2009 Oct 21.

PMID:
19850454
25.

[Penicillin and aminoglycoside in febrile neutropenia].

Torfoss D, Høiby EA, Holte H, Kvaløy S.

Tidsskr Nor Laegeforen. 2008 Dec 4;128(23):2738-40. Review. Norwegian.

26.

Stromal gene signatures in large-B-cell lymphomas.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2008 Nov 27;359(22):2313-23. doi: 10.1056/NEJMoa0802885.

27.

[Courses for cancer patients--15 years' experience at The Montebello Centre in Norway].

Fosså SD, Kvaløy J, Kvaløy S, Loge JH, Dahl AA.

Tidsskr Nor Laegeforen. 2008 Nov 20;128(22):2554-7. Norwegian.

28.

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

Pfreundschuh M, Ho AD, Cavallin-Stahl E, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, Mingrone W, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Corrado C, Scheliga A, Loeffler M, Kuhnt E; MabThera International Trial (MInT) Group.

Lancet Oncol. 2008 May;9(5):435-44. doi: 10.1016/S1470-2045(08)70078-0. Epub 2008 Apr 8.

PMID:
18400558
29.

Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up.

Björkholm M, Hagberg H, Holte H, Kvaloy S, Teerenhovi L, Anderson H, Cavallin-Ståhl E, Myhre J, Pertovaara H, Ost A, Nilsson B, Osby E.

Ann Oncol. 2007 Jun;18(6):1085-9. Epub 2007 Mar 15.

PMID:
17363838
30.

Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial.

Torfoss D, Høiby EA, Tangen JM, Holte H, Bø K, Meyer P, Grøttum K, Weyde K, Lauritzsen GF, Sandstad B, Jacobsen AB, Olsen H, Kvaløy S.

J Antimicrob Chemother. 2007 Apr;59(4):711-7. Epub 2007 Feb 27.

PMID:
17327294
31.

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival.

Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, Liu H, Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC, Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E, Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM.

Blood. 2007 Jun 1;109(11):4599-606. Epub 2007 Feb 13.

32.

Molecular diagnosis of Burkitt's lymphoma.

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM; Lymphoma/Leukemia Molecular Profiling Project.

N Engl J Med. 2006 Jun 8;354(23):2431-42.

33.

Vitamin D deficiency in patients operated on for gastric lymphoma.

Hollender A, Bjøro T, Otto Karlsen K, Kvaloy SO, Nome O, Holte H.

Scand J Gastroenterol. 2006 Jun;41(6):673-81.

PMID:
16716965
34.

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.

Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, López-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M; MabThera International Trial Group.

Lancet Oncol. 2006 May;7(5):379-91.

PMID:
16648042
35.

Quality of life after total or partial gastrectomy for primary gastric lymphoma.

Hjermstad MJ, Hollender A, Warloe T, Karlsen KO, Ikonomo I, Kvaloy S, Nome O, Holte H.

Acta Oncol. 2006;45(2):202-9.

PMID:
16546867
36.

Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction.

Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, Burek C, Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM, Campo E, Rosenwald A; Lymphoma/Leukemia Molecular Profiling Project.

Blood. 2005 Nov 1;106(9):3183-90. Epub 2005 Jul 26.

37.
38.

Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study.

Mishra V, Andresen S, Brinch L, Kvaløy S, Ernst P, Lønset MK, Tangen JM, Wikelund J, Flatum C, Baggerød E, Helle B, Vaaler S, Hagen TP.

Bone Marrow Transplant. 2005 Jun;35(12):1149-53.

PMID:
15880133
39.

[Long-term effects after mantle field radiotherapy for Hodgkin's lymphoma].

Fosså SD, Holte H, Holmen MM, Bjøro T, Langmark F, Hess SL, Kvaløy S.

Tidsskr Nor Laegeforen. 2005 Jan 6;125(1):41-4. Norwegian.

40.

Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.

Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Connors JM, Lansdorp PM, Ouyang Q, Lister TA, Davies AJ, Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH, Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M, Staudt LM.

N Engl J Med. 2004 Nov 18;351(21):2159-69.

42.

Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens.

Smeland S, Blystad AK, Kvaløy SO, Ikonomou IM, Delabie J, Kvalheim G, Hammerstrøm J, Lauritzsen GF, Holte H.

Ann Oncol. 2004 Jul;15(7):1072-8.

PMID:
15205201
44.

Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

Jerkeman M, Anderson H, Dictor M, Kvaløy S, Akerman M, Cavallin-Ståhl E; Nordic Lymphoma Group study.

Ann Hematol. 2004 Jul;83(7):414-9. Epub 2004 Apr 14.

PMID:
15085385
45.

The CARES-SF used for prospective assessment of health-related quality of life after stem cell transplantation.

Hjermstad MJ, Evensen SA, Kvaløy SO, Loge JH, Fayers PM, Kaasa S.

Psychooncology. 2003 Dec;12(8):803-13.

PMID:
14681953
46.

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial.

Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnsen HE, Doorduijn JK, Sydes MR, Kvalheim G.

J Clin Oncol. 2003 Nov 1;21(21):3918-27. Epub 2003 Sep 29.

PMID:
14517188
47.

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM.

J Exp Med. 2003 Sep 15;198(6):851-62.

48.

[Norwegian program for malignant lymphomas].

Kvaløy S.

Tidsskr Nor Laegeforen. 2003 Apr 3;123(7):914. Norwegian. No abstract available.

49.

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM.

Cancer Cell. 2003 Feb;3(2):185-97.

50.

Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study.

Linderoth J, Jerkeman M, Cavallin-Ståhl E, Kvaløy S, Torlakovic E; Nordic Lymphoma Group Study.

Clin Cancer Res. 2003 Feb;9(2):722-8.

Supplemental Content

Loading ...
Support Center